For the first time in 30 years, a new drug class known as the CGRP-Antagonists (calcitonin gene-related peptide) has emerged.

The software-based intervention aims to reduce brain hypersensitivity in patients with migraine by modulating responses to environmental and internal stimuli through a 12-week program.

Lasmiditan is a promising treatment for menstrual migraine, offering sustained pain relief comparable to or exceeding that of triptans. However, further research is needed to fully assess its safety ...

Clinical evidence supports early, preventive treatment for migraine. It's important to have a variety of safe and effective treatment options- that are affordable, promote adherence and help prevent ...

Migraine disease affects millions of Americans, but treatments often cause side effects that hinder sufferers' ability to function.

The following is a summary of “A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide ...

The FDA has accepted for review the sBLA for fremanezumab-vfrm for the prevention of episodic migraine in pediatric patients aged 6 to-17 years weighing at least 45 kg.

Compared with sham, transnasal dry air flow at 10 L per minute using the Mi-Helper device was effective in treating acute ...

Delivering room-temperature air through the nose to cool the sphenopalatine ganglion taps into a powerful neuromodulatory ...

Click Therapeutics has collected a groundbreaking green light from the FDA for the agency’s first prescription digital ...